| For: | Ma JH, Patrut E, Schmidt J, Knaebel HP, Büchler MW, Märten A. Synergistic effects of interferon-alpha in combination with chemoradiation on human pancreatic adenocarcinoma. World J Gastroenterol 2005; 11(10): 1521-1528 [PMID: 15770730 DOI: 10.3748/wjg.v11.i10.1521] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v11/i10/1521.htm |
| Number | Citing Articles |
| 1 |
Andrew Sharabi, Joseph Herman, Vivian Weiss, Daniel Laheru, Richard Tuli. Role of radiotherapy in combination with chemotherapy, targeted therapy, and immunotherapy in the management of pancreatic cancer. Journal of Radiation Oncology 2013; 2(4) doi: 10.1007/s13566-013-0125-4
|
| 2 |
Yifan Zhu, Igor Tibensky, Jan Schmidt, Eduard Ryschich, Angela Märten. Interferon-α Enhances Antitumor Effect of Chemotherapy in an Orthotopic Mouse Model for Pancreatic Adenocarcinoma. Journal of Immunotherapy 2008; 31(7) doi: 10.1097/CJI.0b013e3181818769
|
| 3 |
Gen Kimura, Hideaki Ijichi, Makoto Sano, Genso Notoya, Koji Miyabayashi, Ryota Takahashi, Takahiro Kishikawa, Mitsuhiro Fujishiro. Blockade of CC chemokine receptor 2 suppresses pancreatic cancer progression through the interaction with macrophages in the tumor microenvironment. Scientific Reports 2025; 15(1) doi: 10.1038/s41598-025-32222-4
|
| 4 |
Wen-Jia Wang, Si-Hao Qin, Ji-Wei Zhang, Yue-Yao Jiang, Jin-Nan Zhang, Lei Zhao. Combination Doxorubicin and Interferon-α Therapy Stimulates Immunogenicity of Murine Pancreatic Cancer Panc02 Cells via Up-regulation of NKG2D ligands and MHC Class I. Asian Pacific Journal of Cancer Prevention 2014; 15(22) doi: 10.7314/APJCP.2014.15.22.9667
|
| 5 |
Christopher J. LaRocca, Joohee Han, Tatyana Gavrikova, Leonard Armstrong, Amanda R. Oliveira, Ryan Shanley, Selwyn M. Vickers, Masato Yamamoto, Julia Davydova. Oncolytic adenovirus expressing interferon alpha in a syngeneic Syrian hamster model for the treatment of pancreatic cancer. Surgery 2015; 157(5) doi: 10.1016/j.surg.2015.01.006
|
| 6 |
Stephanie Booy, Leo Hofland, Casper van Eijck. Potentials of Interferon Therapy in the Treatment of Pancreatic Cancer. Journal of Interferon & Cytokine Research 2015; 35(5) doi: 10.1089/jir.2014.0157
|
| 7 |
Angela Märten, Markus W. Büchler, Jan Schmidt. Radiochemoimmunotherapy for pancreatic cancer. The American Journal of Surgery 2007; 194(4) doi: 10.1016/j.amjsurg.2007.05.012
|
| 8 |
Marjolein J.M. Morak, Peter M. van Koetsveld, Roland Kanaar, Leo J. Hofland, Casper H.J. van Eijck. Type I interferons as radiosensitisers for pancreatic cancer. European Journal of Cancer 2011; 47(13) doi: 10.1016/j.ejca.2011.03.009
|
| 9 |
Jan Schmidt, Dirk Jäger, Kartin Hoffmann, Markus W. Büchler, Angela Märten. Impact of Interferon-α in Combined Chemoradioimmunotherapy for Pancreatic Adenocarcinoma (CapRI): First Data From the Immunomonitoring. Journal of Immunotherapy 2007; 30(1) doi: 10.1097/01.cji.0000211317.15278.27
|
| 10 |
Eva Jöst, Wynand P. Roos, Bernd Kaina, Heinz Schmidberger. Response of pancreatic cancer cells treated with interferon-α or β and co-exposed to ionising radiation. International Journal of Radiation Biology 2010; 86(9) doi: 10.3109/09553002.2010.481321
|
| 11 |
Jan Schmidt, Emilia M. Patrut, Jianhua Ma, Dirk Jäger, Hanns-Peter Knaebel, Markus W. Büchler, Angela Märten. Immunomodulatory impact of interferon-alpha in combination with chemoradiation of pancreatic adenocarcinoma (CapRI). Cancer Immunology, Immunotherapy 2006; 55(11) doi: 10.1007/s00262-006-0140-z
|
| 12 |
Angela Märten, Jan Schmidt, Jennifer Ose, Sabine Harig, Ulrich Abel, Marc W Münter, Dirk Jäger, Helmut Friess, Julia Mayerle, Guido Adler, Thomas Seufferlein, Thomas Gress, Roland Schmid, Markus W Büchler. A Randomized Multicentre Phase II Trial Comparing Adjuvant Therapy in Patients with Interferon Alpha-2b and 5-FU Alone or in Combination with Either External Radiation Treatment and Cisplatin (CapRI) or Radiation alone regarding Event-Free Survival – CapRI-2. BMC Cancer 2009; 9(1) doi: 10.1186/1471-2407-9-160
|
| 13 |
Yifan Zhu, Igor Tibensky, Jan Schmidt, Thilo Hackert, Eduard Ryschich, Dirk Jäger, Markus W. Büchler, Angela Märten. Interferon-α in Combination With Chemotherapy has Potent Antiangiogenic Properties in an Orthotopic Mouse Model for Pancreatic Adenocarcinoma. Journal of Immunotherapy 2008; 31(1) doi: 10.1097/CJI.0b013e318157c682
|
| 14 |
Jan Schmidt, Ulrich Abel, Jürgen Debus, Sabine Harig, Katrin Hoffmann, Thomas Herrmann, Detlef Bartsch, Justus Klein, Ulrich Mansmann, Dirk Jäger, Lorenzo Capussotti, Reiner Kunz, Markus W. Büchler. Open-Label, Multicenter, Randomized Phase III Trial of Adjuvant Chemoradiation Plus Interferon Alfa-2b Versus Fluorouracil and Folinic Acid for Patients With Resected Pancreatic Adenocarcinoma. Journal of Clinical Oncology 2012; 30(33) doi: 10.1200/JCO.2011.38.2960
|
| 15 |
Shuhei Shinoda, Nikita S. Sharma, Naohiko Nakamura, Kazuho Inoko, Mizuho Sato‐Dahlman, Paari Murugan, Julia Davydova, Masato Yamamoto. Interferon‐expressing oncolytic adenovirus + chemoradiation inhibited pancreatic cancer growth in a hamster model. Cancer Science 2023; 114(9) doi: 10.1111/cas.15903
|